Humacyte (HUMA) Aktienübersicht
Humacyte, Inc. und seine Tochtergesellschaften entwickeln und produzieren handelsübliche, implantierbare und biotechnologisch hergestellte menschliche Gewebe für die Behandlung von Krankheiten und Zuständen an einer Reihe von anatomischen Stellen in verschiedenen therapeutischen Bereichen. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 0/6 |
| Künftiges Wachstum | 5/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 4/6 |
| Dividenden | 0/6 |
HUMA Community Fair Values
Create NarrativeSee what 45 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Humacyte, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$0.69 |
| 52-Wochen-Hoch | US$2.84 |
| 52-Wochen-Tief | US$0.55 |
| Beta | 2.52 |
| 1 Monat Veränderung | -34.25% |
| 3 Monate Veränderung | 3.52% |
| 1 Jahr Veränderung | -69.97% |
| 3 Jahre Veränderung | -77.11% |
| 5 Jahre Veränderung | -93.06% |
| Veränderung seit IPO | -92.83% |
Aktuelle Nachrichten und Updates
HUMA: V012 Phase 3 Dialysis Data Will Drive Future Repricing
Humacyte's updated analyst price targets, which now range from $1.25 to $4.00, reflect mixed revisions as analysts weigh positive interim V012 data and potential AV access indication expansion against updated assumptions for growth, profitability, and future P/E expectations. Analyst Commentary on Humacyte Recent street research on Humacyte reflects a wide range of expectations, with some analysts trimming price targets even as they acknowledge positive interim V012 data and potential indication expansion in dialysis access.
HUMA: V012 Dialysis Data Will Shape Future Indication Expansion Prospects
Analysts have reset Humacyte’s fair value estimate from $7.86 to $2.05, citing updated assumptions on growth, margins, and long term P/E in light of recent price target revisions that reflect both encouraging V012 data and moderated expectations for the company’s acellular vessel portfolio. Analyst Commentary Recent Street research on Humacyte highlights mixed views, with some analysts leaning optimistic on the acellular vessel opportunity and others resetting expectations, which collectively helps explain the lower fair value estimate.Recent updates
HUMA: V012 Phase 3 Dialysis Data Will Drive Future Repricing
Humacyte's updated analyst price targets, which now range from $1.25 to $4.00, reflect mixed revisions as analysts weigh positive interim V012 data and potential AV access indication expansion against updated assumptions for growth, profitability, and future P/E expectations. Analyst Commentary on Humacyte Recent street research on Humacyte reflects a wide range of expectations, with some analysts trimming price targets even as they acknowledge positive interim V012 data and potential indication expansion in dialysis access.HUMA: V012 Dialysis Data Will Shape Future Indication Expansion Prospects
Analysts have reset Humacyte’s fair value estimate from $7.86 to $2.05, citing updated assumptions on growth, margins, and long term P/E in light of recent price target revisions that reflect both encouraging V012 data and moderated expectations for the company’s acellular vessel portfolio. Analyst Commentary Recent Street research on Humacyte highlights mixed views, with some analysts leaning optimistic on the acellular vessel opportunity and others resetting expectations, which collectively helps explain the lower fair value estimate.Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist
Summary Humacyte, Inc. remains rated Hold despite a DoD funding catalyst revealed today, as commercial traction for Symvess is not yet proven. Symvess is the only FDA-approved human-derived bioengineered blood vessel, but Q3 revenue was just $700k, and uptake remains limited. HUMA's funding runway is constrained, with recent capital raises offset by high R&D spending; further dilution or cost cuts may be needed. Key 2026 catalysts are dialysis data readouts and BLA submissions, not the recent DoD news, given ongoing risks and modest near-term sales. Read the full article on Seeking AlphaHere's Why Humacyte (NASDAQ:HUMA) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is Humacyte (NASDAQ:HUMA) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade)
Summary Humacyte's stock has dropped 29% since December, despite FDA approval of Symvess. Symvess faces slow adoption due to the need for long-term outcomes data. Humacyte's financial health is precarious, with high operating expenses and a cash runway extending only into late 2025, raising concerns about future dilution. Given these challenges, I downgrade HUMA to "Sell," as achieving a return on investment for Symvess seems unlikely without significant financial strain. Read the full article on Seeking AlphaHumacyte: Expect A Slow Launch, But Vascular Trauma Indication Is Just A Beginning
Summary Humacyte, Inc. arrived on the Nasdaq in 2021 via a SPAC deal and reappeared on my radar after the Symvess approval in vascular trauma repair. Platform enabling off-the-shelf bioengineered tissues could transform the field of regenerative medicine. There's a large addressable market across 3 lead indications alone (trauma, dialysis & PAD) + significant optionality for more complex projects (i.e., biovascular pancreas in diabetes). Key concerns include slow launch out of the gate, continued cash burn & dilution, competition, and manufacturing capacity. My Action Plan: I remain on the sidelines for HUMA stock and will continue to monitor launch metrics as well as pipeline progress. Read the full article on Seeking AlphaHumacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)
Summary Humacyte stock has dropped 46% since July, mainly due to FDA review delays and mixed Phase 3 trial results for their ATEVs in hemodialysis. Despite FDA approval of Symvess for vascular trauma, its market potential is limited, and adoption is expected to be slow and costly. Phase 3 trial data for ATEVs in hemodialysis patients showed higher thrombosis and infection rates, raising concerns about its safety and efficacy. Humacyte's financial situation remains precarious, with high operating expenses and potential ongoing dilution, leading to a downgrade on HUMA stock from "buy" to "hold". Read the full article on Seeking AlphaHumacyte: FDA Waiting Game Bleeding Company Dry
Summary Humacyte's innovative ATEV technology shows promise but faces delays in FDA approval, initially expected in Aug, causing financial strain and uncertainty about its market potential. Despite strong clinical data, the FDA's postponement of the ATEV approval has left Humacyte in a precarious financial position, forcing it to raise ~$45m since August. The lack of a clear FDA timeline creates significant risk for investors, leading to a downgrade from "buy" to "hold" due to potential further delays. The market opportunity for ATEVs remains uncertain, questioning whether Humacyte stock can achieve significant upside even if FDA approval is granted. Read the full article on Seeking AlphaHumacyte: Navigating The FDA Uncertainty And ATEV's Potential
Summary Humacyte’s acellular tissue engineered vessel (ATEV) shows promise in trauma and dialysis, with positive clinical trial results and potential FDA approval by year-end. Despite FDA delays, Humacyte remains optimistic but faces financial instability, with only $43.6 million in cash, supporting operations for 1.5 quarters. HUMA stock is rated as a moderate "Buy" for high-risk tolerant investors, given the potential for FDA approval and significant market capture in trauma. Risks include potential FDA rejection, financial distress, and management's recent share sales, which warrant cautious investment consideration. Read the full article on Seeking AlphaWill Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Humacyte: Pioneering Vascular Solutions With High-Stakes Potential
Summary Humacyte is developing HAVs for multiple indications, showing promising clinical outcomes, and receiving FDA RMAT designation for faster approval processes. The market for vascular repairs is large and growing, with Humacyte's HAVs positioned as a potentially superior option to traditional treatments. Financially, Humacyte holds sufficient short-term assets but faces significant long-term liabilities and a potential cash crunch within a year. I recommend buying HUMA as a speculative, high-risk/high-reward addition to a diversified investment portfolio. Read the full article on Seeking AlphaAktionärsrenditen
| HUMA | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -2.3% | -2.3% | 0.8% |
| 1Y | -70.0% | 35.8% | 20.6% |
Rendite im Vergleich zur Industrie: HUMA unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 35.8% erzielte.
Rendite vs. Markt: HUMA hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 20.6 erzielte.
Preisvolatilität
| HUMA volatility | |
|---|---|
| HUMA Average Weekly Movement | 18.3% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: Der Aktienkurs von HUMA war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: HUMADie wöchentliche Volatilität (18%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2004 | 184 | Laura Niklason | www.humacyte.com |
Humacyte, Inc. und seine Tochtergesellschaften sind in der Entwicklung und Herstellung von standardisierten, implantierbaren und biotechnologisch hergestellten menschlichen Geweben für die Behandlung von Krankheiten und Zuständen an verschiedenen anatomischen Stellen in verschiedenen therapeutischen Bereichen tätig. Das Unternehmen nutzt seine firmeneigene und wissenschaftliche Technologieplattform, um azelluläre menschliche Gefäße (HAV) zu entwickeln und herzustellen, die in Patienten implantiert werden können, ohne eine Fremdkörperreaktion auszulösen oder zu einer Immunabstoßung zu führen. Das Unternehmen entwickelt ein Portfolio von HAVs für den Markt der Gefäßreparatur, -rekonstruktion und des Gefäßersatzes, einschließlich Gefäßverletzungen, arteriovenöser Zugänge für die Hämodialyse, peripherer Arterienerkrankungen, pädiatrischer Herzchirurgie und koronarer Bypass-Transplantation, sowie für die Verabreichung von Zelltherapien, einschließlich der Transplantation von Inselzellen der Bauchspeicheldrüse zur Behandlung von Diabetes Typ 1.
Humacyte, Inc.'s Grundlagenzusammenfassung
| HUMA grundlegende Statistiken | |
|---|---|
| Marktanteil | US$187.05m |
| Gewinn(TTM) | -US$95.22m |
| Umsatz(TTM) | US$2.02m |
Ist HUMA zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| HUMA Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$2.02m |
| Kosten der Einnahmen | US$83.74m |
| Bruttogewinn | -US$81.72m |
| Sonstige Ausgaben | US$13.49m |
| Gewinn | -US$95.22m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.35 |
| Bruttomarge | -4,053.72% |
| Nettogewinnspanne | -4,723.07% |
| Schulden/Eigenkapital-Verhältnis | 313.8% |
Wie hat sich HUMA auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/12 06:46 |
| Aktienkurs zum Tagesende | 2026/07/10 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Humacyte, Inc. wird von 9 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Matthew Miksic | Barclays |
| Bruce Jackson | Benchmark Company |
| Michael Gorman | BTIG |